Population pharmacokinetics of dolutegravir in HIV‐infected treatment‐naive patients

Abstract

A population model that adequately characterizes dolutegravir pharmacokinetics has been developed. No dolutegravir dose adjustment by patient covariates is necessary in HIV-infected treatment-naive patients.